Symbols

MDGL

Madrigal·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Double Bottom

Three Black Crows

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MDGL

Madrigal Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis

Industry

Biological Technology

Established Date

Listing Date

02/06/2007

Exchange

NASDAQ Stock Exchange

Full-time Employees

915

Fiscal Year Ends

12-31

Website

www.madrigalpharma.com

Security Type

Common stock

Office address

Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania

Business

Introduction

Madrigal Pharmaceuticals, Inc., was established in March 2000 and began operations in July 2001. The company is a biopharmaceutical company focused on providing new treatments for metabolic dysfunction-related steatohepatitis. Steatohepatitis is a serious liver disease with highly unmet medical needs that can lead to cirrhosis, liver failure, cancer, liver transplant needs and premature death. The company's drug, Rezifra, is a once-daily oral liver-directed thyroid hormone receptor beta agonist designed to target a key underlying cause of MASH.

Company Financials

EPS

MDGL has released its 2025 Q4 earnings. EPS was reported at -2.57, versus the expected -0.6, missing expectations. The chart below visualizes how MDGL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MDGL has released its 2025 Q4 earnings report, with revenue of 321.08M, reflecting a YoY change of 210.77%, and net profit of -58.58M, showing a YoY change of 1.42%. The Sankey diagram below clearly presents MDGL's revenue sources and cost distribution.